Prostatic artery embolization versus conventional TUR-P in the treatment of benign prostatic hyperplasia: protocol for a prospective randomized non-inferiority trial

Dominik Abt, Livio Mordasini, Lukas Hechelhammer, Thomas M Kessler, Hans-Peter Schmid, Daniel S Engeler, Dominik Abt, Livio Mordasini, Lukas Hechelhammer, Thomas M Kessler, Hans-Peter Schmid, Daniel S Engeler

Abstract

Background: Benign prostatic hyperplasia (BPH) is a prevalent entity in elderly men and transurethral resection of the prostate (TURP) still represents the gold standard of surgical treatment despite its considerable perioperative morbidity. Recently, prostatic artery embolization (PAE) was described as a novel effective and less invasive treatment alternative. Despite promising first results, PAE still has to be considered experimental due to a lack of good quality studies. Prospective randomized controlled trials comparing PAE with TUR-P are highly warranted.

Methods/design: This is a single-centre, prospective, randomized, non-inferiority trial comparing treatment effects and adverse events of PAE and TURP in a tertiary referral centre. One hundred patients who are electable for both treatment options are randomized to either PAE or TURP. Changes of the International Prostate Symptom Score (IPSS) after 3 months are defined as primary endpoint. Changes in bladder diaries, laboratory analyses, urodynamic investigations and standardised questionnaires are assessed as secondary outcome measures. In addition contrast-enhanced magnetic resonance imaging of the pelvis before and after the interventions will provide crucial information regarding morphological changes and vascularisation of the prostate. Adverse events will be assessed on every follow-up visit in both treatment arms according to the National Cancer Institute Common Terminology Criteria for Adverse events and the Clavien classification.

Discussion: The aim of this study is to assess whether PAE represents a valid treatment alternative to TURP in patients suffering from BPH in terms of efficacy and safety.

Trial registration: ClinicalTrials.gov NCT02054013.

Figures

Figure 1
Figure 1
Timetable and characteristics of study visits.

References

    1. Levy A, Samraj GP. Benign prostatic hyperplasia: when to ‘watch and wait’, when and how to treat. Cleve Clin J Med. 2007;74(Suppl 3):S15–S20. doi: 10.3949/ccjm.74.Suppl_3.S15.
    1. Eckhardt MD, Van Venrooij GE, Van Melick HH, Boon TA. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. J Urol. 2001;166(2):563–568. doi: 10.1016/S0022-5347(05)65985-X.
    1. Michel MC, Mehlburger L, Bressel HU, Schumacher H, Schafers RF, Goepel M. Tamsulosin treatment of 19,365 patients with lower urinary tract symptoms: does co-morbidity alter tolerability? J Urol. 1998;160(3 Pt 1):784–791.
    1. Reich O, Gratzke C, Bachmann A, Seitz M, Schlenker B, Hermanek P, Lack N, Stief CG. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol. 2008;180(1):246–249. doi: 10.1016/j.juro.2008.03.058.
    1. Sun F, Sanchez FM, Crisostomo V, Lima JR, Luis L, Garcia-Martinez V, Lopez-Sanchez C, Uson J, Maynar M. Benign prostatic hyperplasia: transcatheter arterial embolization as potential treatment–preliminary study in pigs. Radiology. 2008;246(3):783–789. doi: 10.1148/radiol.2463070647.
    1. Jeon GS, Won JH, Lee BM, Kim JH, Ahn HS, Lee EJ, Park SI, Park SW. The effect of transarterial prostate embolization in hormone-induced benign prostatic hyperplasia in dogs: a pilot study. J Vasc Interv Radiol. 2009;20(3):384–390. doi: 10.1016/j.jvir.2008.11.014.
    1. Lang EK, Deutsch JS, Goodman JR, Barnett TF, Lanasa JA, Jr, Duplessis GH. Transcatheter embolization of hypogastric branch arteries in the management of intractable bladder hemorrhage. J Urol. 1979;121(1):30–36.
    1. DeMeritt JS, Elmasri FF, Esposito MP, Rosenberg GS. Relief of benign prostatic hyperplasia-related bladder outlet obstruction after transarterial polyvinyl alcohol prostate embolization. J Vasc Interv Radiol. 2000;11(6):767–770. doi: 10.1016/S1051-0443(07)61638-8.
    1. Carnevale FC, Antunes AA, Da Motta Leal Filho JM, De Oliveira Cerri LM, Baroni RH, Marcelino AS, Freire GC, Moreira AM, Srougi M, Cerri GG. Prostatic artery embolization as a primary treatment for benign prostatic hyperplasia: preliminary results in two patients. Cardiovasc Intervent Radiol. 2010;33(2):355–361. doi: 10.1007/s00270-009-9727-z.
    1. Rio Tinto H, Martins Pisco J, Bilhim T, Duarte M, Fernandes L, Pereira J, Campos Pinheiro L. Prostatic artery embolization in the treatment of benign prostatic hyperplasia: short and medium follow-up. Tech Vasc Interv Radiol. 2012;15(4):290–293. doi: 10.1053/j.tvir.2012.09.005.
    1. Carnevale FC, Da Motta-Leal-Filho JM, Antunes AA, Baroni RH, Marcelino AS, Cerri LM, Yoshinaga EM, Cerri GG, Srougi M. Quality of life and clinical symptom improvement support prostatic artery embolization for patients with acute urinary retention caused by benign prostatic hyperplasia. J Vasc Interv Radiol. 2013;24(4):535–542. doi: 10.1016/j.jvir.2012.12.019.
    1. Kurbatov D, Russo GI, Lepetukhin A, Dubsky S, Sitkin I, Morgia G, Rozhivanov R, Cimino S, Sansalone S. Prostatic artery embolization for prostate volume greater than 80 cm(3): results from a single-center prospective study. Urology. 2014;84(2):400–404. doi: 10.1016/j.urology.2014.04.028.
    1. Bilhim T, Pisco J, Campos Pinheiro L, Rio Tinto H, Fernandes L, Pereira JA, Duarte M, Oliveira AG. Does polyvinyl alcohol particle size change the outcome of prostatic arterial embolization for benign prostatic hyperplasia? Results from a single-center randomized prospective study. J Vasc Interv Radiol. 2013;24(11):1595–1602 e1591. doi: 10.1016/j.jvir.2013.06.003.
    1. Martins Pisco J, Pereira J, Rio Tinto H, Fernandes L, Bilhim T. How to perform prostatic arterial embolization. Tech Vasc Interv Radiol. 2012;15(4):286–289. doi: 10.1053/j.tvir.2012.09.002.
    1. Carnevale FC, Antunes AA. Prostatic artery embolization for enlarged prostates due to benign prostatic hyperplasia. How I do it. Cardiovasc Intervent Radiol. 2013;36(6):1452–1463. doi: 10.1007/s00270-013-0680-5.
    1. AP J, Bilhim T, Duarte M, Rio Tinto H, Fernandes L, Martins Pisco J. Patient selection and counseling before prostatic arterial embolization. Tech Vasc Interv Radiol. 2012;15(4):270–275. doi: 10.1053/j.tvir.2012.09.003.
    1. Schreuder SM, Scholtens AE, Reekers JA, Bipat S. The role of prostatic arterial embolization in patients with benign prostatic hyperplasia: a systematic review. Cardiovasc Intervent Radiol. 2014;37(5):1198–1219. doi: 10.1007/s00270-014-0948-4.
    1. Gao YA, Huang Y, Zhang R, Yang YD, Zhang Q, Hou M, Wang Y. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate–a prospective, randomized, and controlled clinical trial. Radiology. 2014;270(3):920–928. doi: 10.1148/radiol.13122803.
    1. Engeler DS, Schwab C, Neyer M, Grun T, Reissigl A, Schmid HP. Bipolar versus monopolar TURP: a prospective controlled study at two urology centers. Prostate Cancer Prostatic Dis. 2010;13(3):285–291. doi: 10.1038/pcan.2010.1.
    1. World Medical Association . Declaration of Helsinki - ethical principles for medical research involving human subjects. 1964.
    1. International conference on harmonisation: Good clinical practice guideline.
    1. Swiss Academy of Medical Sciences . Guideline - concerning scientific research involving human beings. 2009.
    1. The Federal Authorities of the Swiss Confederation . Bundesgesetz über den Datenschutz (DSG) vom 19. Juni 1992, Stand. 01.01.2014. 1992.
    1. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–213. doi: 10.1097/.
Pre-publication history
    1. The pre-publication history for this paper can be accessed here:

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren